|
業務類別
|
-- |
|
業務概覽
|
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China. |
| 公司地址
| 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN |
| 電話號碼
| +86 5353573511 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.remegen.com |
| 員工數量
| 3497 |
| Mr. Qingkai Wen |
Director and Board Secretary |
-- |
28/03/2026 |
| Dr. Jianmin Fang, PhD |
Director, Chief Executive Officer and General Manager |
-- |
28/03/2026 |
|
|
| Mr. Xianjing Hao |
Independent Director |
28/03/2026 |
| Dr. Liqiang Wang |
Director |
28/03/2026 |
| Mr. Jian Lin |
Director |
28/03/2026 |
| Mr. Weidong Wang |
Executive Chairman of Board |
28/03/2026 |
| Dr. Xiaodi Su, PhD |
Director |
28/03/2026 |
| Mr. Yunjin Chen |
Independent Director |
28/03/2026 |
| Mr. Qingkai Wen |
Director and Board Secretary |
28/03/2026 |
| Mr. Guobin Huang |
Independent Director |
28/03/2026 |
| Dr. Jianmin Fang, PhD |
Director, Chief Executive Officer and General Manager |
28/03/2026 |
|
|
|
|
